Zepbound vs Saxenda: Cost, Access, and Which Is Right for You

How Much Weight Will You Actually Lose?

The efficacy gap between these two drugs is real and clinically meaningful. In SURMOUNT-1, adults taking tirzepatide 15 mg lost a mean of 20.9% of body weight over 72 weeks compared with 3.1% on placebo. The SCALE Obesity and Prediabetes trial showed liraglutide 3 mg producing a mean 8.0% body-weight reduction at 56 weeks versus 2.6% on placebo.

That is not a small difference. For a 200-lb woman, Zepbound at its highest dose predicts roughly 42 lbs lost; Saxenda predicts roughly 16 lbs.

Why Tirzepatide Works Harder

Zepbound activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual action appears to produce greater appetite suppression and a stronger effect on energy expenditure than GLP-1 alone. Saxenda acts only on the GLP-1 receptor, which still produces meaningful weight loss but from a narrower biological lever.

No direct head-to-head randomized trial between tirzepatide 15 mg and liraglutide 3 mg has been published in the weight-loss setting as of January 2025. The numbers above come from separate trials with different populations, durations, and eligibility criteria. Comparing them gives a directional signal, not a precise difference.

What the Numbers Mean for Women Specifically

Women in SURMOUNT-1 were not analyzed as a separate published subgroup in the primary paper, which is a genuine evidence gap worth naming. The broader GLP-1 literature, including SCALE, shows similar relative weight-loss percentages between sexes, but women tend to start from a different absolute weight, which changes the absolute pounds lost. Women also experience hormonal fluctuations that affect appetite, gastric motility, and insulin sensitivity across the cycle and life stages, and neither trial was designed to capture those effects.

Cost and Access: The Real-World Numbers

Zepbound Cost

Zepbound launched in late 2023 at a list price near $1,060 per month for the 2.5 mg and 5 mg starter vials. Eli Lilly offers a savings card for commercially insured patients that can bring out-of-pocket cost to $25 per month if your insurance covers it, or $550 per month if it does not. Lilly also sells single-dose vials directly through LillyDirect at reduced prices for cash-pay patients, currently ranging from approximately $399 to $549 per month depending on dose.

Medicare Part D does not cover Zepbound for obesity alone. This matters enormously for women in their 60s and older who are postmenopausal and may have the highest metabolic risk.

Saxenda Cost

Saxenda's list price sits near $1,400 per month, higher than Zepbound, which surprises most patients. Novo Nordisk offers a savings program that can reduce cost to $25 to $99 per month for eligible commercially insured patients. A generic liraglutide for weight loss does not exist as of January 2025, though liraglutide 1.8 mg is available for type 2 diabetes under the brand Victoza.

Insurance Coverage: Where Things Get Complicated

Coverage varies dramatically by plan and employer. As of 2025:

| Drug | Typical commercial coverage | Medicare Part D | State Medicaid | |---|---|---|---| | Zepbound (tirzepatide) | Variable; prior auth common | Not covered for obesity | Varies by state | | Saxenda (liraglutide 3 mg) | Variable; prior auth common | Not covered for obesity | Varies by state |

Both drugs typically require prior authorization documenting a BMI ≥30, or BMI ≥27 with a weight-related comorbidity such as hypertension, type 2 diabetes, or sleep apnea. Women with PCOS may qualify under the insulin-resistance or metabolic-syndrome pathway, but your prescriber needs to document this explicitly.

Compounded Tirzepatide and Liraglutide

During tirzepatide shortages, FDA allowed 503B outsourcing facilities to compound tirzepatide. Compounded versions cost roughly $150 to $300 per month depending on dose and pharmacy. The FDA shortage designation for tirzepatide was resolved in early 2025, which means compounding from outsourcing facilities is no longer federally permitted under the shortage pathway, though the legal field is actively shifting. Compounded liraglutide for weight loss has a similar regulatory history.

If you are considering compounded versions of either drug, ask your prescriber to confirm the current FDA status, verify the 503A or 503B pharmacy license, and obtain a certificate of analysis for every batch.

Women-Specific Physiology: What Changes the Equation

The Menstrual Cycle and GLP-1 Drugs

Progesterone slows gastric motility. During the luteal phase (roughly days 15 to 28), you may find nausea from either drug worse than in the follicular phase. No clinical trial has formally tracked GLP-1 side effects by cycle phase, which is a clear evidence gap. Anecdotally, many women report that starting a new dose at the beginning of their follicular phase, when progesterone is lowest, reduces first-week nausea.

PCOS

Polycystic ovary syndrome affects 8 to 13% of reproductive-age women globally. Insulin resistance is central to PCOS pathophysiology. Both liraglutide and tirzepatide improve insulin sensitivity and reduce androgen levels indirectly by lowering insulin. Small trials of liraglutide in PCOS showed improvements in menstrual regularity and androgen markers. Tirzepatide data in PCOS specifically is limited as of January 2025, extrapolated primarily from SURMOUNT-1 subgroups that included women with metabolic syndrome.

Women with PCOS who lose weight on either drug may see a return or normalization of ovulation. This is clinically important: if you are not trying to conceive, effective contraception is essential because you may not be aware that your fertility has returned.

Perimenopause and Post-Menopause

Estrogen withdrawal during perimenopause shifts fat distribution toward central adiposity and raises cardiovascular risk. GLP-1 drugs address this directly through weight and metabolic effects. The Menopause Society does not currently have a formal position statement on GLP-1 drugs in menopause management, though several expert commentaries in Menopause journal have noted the biological rationale.

For postmenopausal women, bone density deserves attention. Rapid weight loss of any kind, including from GLP-1 drugs, may reduce bone mineral density. SURMOUNT-1 did not show a significant increase in fracture risk, but the 72-week duration is not long enough to fully characterize fracture outcomes in older women. If you are postmenopausal, discuss baseline DEXA scanning with your clinician before starting.

Thyroid Health

Both drugs carry a black-box warning for thyroid C-cell tumors based on rodent data. Neither drug is approved for women with a personal or family history of medullary thyroid carcinoma or MEN2. Postpartum thyroiditis and Hashimoto's thyroiditis are common in women; neither condition is a contraindication, but your thyroid labs should be current before starting.

Pregnancy, Lactation, and Contraception

Both Zepbound and Saxenda are contraindicated in pregnancy. This is not a precautionary soft warning. Animal studies show fetal harm, and weight loss during pregnancy is generally harmful to fetal development regardless of mechanism.

Pregnancy Category and Human Data

The FDA label for Zepbound states that tirzepatide caused adverse embryo-fetal effects in animal studies at exposures below the maximum recommended human dose. Human data are insufficient because pregnant women are appropriately excluded from trials. Liraglutide carries a similar designation per the Saxenda prescribing information.

If you become pregnant while taking either drug, stop immediately and contact your obstetric provider. Neither drug requires a structured washout period before pregnancy attempts in current labeling, but many clinicians recommend stopping Zepbound at least two months before a planned conception attempt given its long half-life of approximately five days.

Breastfeeding

Neither drug has adequate human lactation data. Animal studies suggest liraglutide is present in rat milk. Given the unknown risk to a nursing infant, both drugs should be avoided during breastfeeding. If weight management is a postpartum priority, discuss timing with your OB or a dietitian, and consider waiting until you have completed breastfeeding.

Contraception Requirements

Women taking either drug for weight loss should use reliable contraception. For women with PCOS who are using these drugs specifically to restore ovulatory cycles as part of a fertility plan, stopping before attempting conception is necessary. Women taking combined oral contraceptives should know that vomiting from dose escalation may reduce pill absorption; a backup method or an IUD may be preferable during the first months of treatment.

A Life-Stage Framework: Who Is Each Drug Right For?

No single article can replace a one-on-one clinical assessment, but this framework gives you a starting structure for the conversation with your provider.

Zepbound May Be the Better First Choice If You:

• Have a BMI ≥30 (or ≥27 with a comorbidity) and want the highest probability of significant weight loss
• Can tolerate a weekly injection and prefer less frequent dosing over daily
• Have commercial insurance that covers it or can access LillyDirect cash pricing
• Are in perimenopause or post-menopause with central adiposity and metabolic risk
• Have insulin resistance or prediabetes alongside obesity
• Are not pregnant, not planning pregnancy in the next two to three months, and are using reliable contraception

Saxenda May Make More Sense If You:

• Have already been prescribed liraglutide for diabetes (Victoza) and want to transition to the weight-loss dose
• Have a prescriber or plan that has an established Saxenda approval pathway and Zepbound prior auth is failing
• Prefer daily dosing for the psychological structure it provides (some women report this)
• Are earlier in a clinical pathway where your plan covers Saxenda but not Zepbound
• Need a medication with a longer post-market safety record (Saxenda was approved in 2014; Zepbound in 2023)

Neither Drug Is Appropriate If You:

• Are pregnant or actively trying to conceive in the near term
• Are currently breastfeeding
• Have a personal or family history of medullary thyroid carcinoma or MEN2
• Have a history of pancreatitis (use with caution; both carry a warning)
• Have severe gastroparesis

Side-Effect Profiles: What Women Report

Both drugs share the GLP-1 class side-effect signature: nausea, vomiting, diarrhea, constipation, and injection-site reactions. The incidence is broadly similar in structure, though SURMOUNT-1 reported nausea in about 31% of participants at the highest tirzepatide dose, and SCALE reported nausea in approximately 40% of liraglutide participants during dose escalation.

Nausea is worse during dose escalation for both. Women in the luteal phase of their cycle, or women experiencing perimenopausal GI changes, may find nausea more pronounced. Constipation from Zepbound is frequently reported and can be confused with the bloating that is common in perimenopause; adequate hydration and fiber are the first-line response before adding a laxative.

Gallbladder disease is a class-level concern. Rapid weight loss increases bile lithogenicity. Both Zepbound and Saxenda labeling includes a warning for cholelithiasis. Women already have a higher lifetime risk of gallstones than men, roughly twice the rate, so this is not a trivial point.

Hair thinning (telogen effluvium) from rapid weight loss appears to be a weight-loss effect rather than a drug-specific effect. It typically begins two to four months after significant weight loss and resolves over six to twelve months.

Switching Between Drugs

Can you switch from Saxenda to Zepbound, or the other way? Yes, in most cases, though there is no published protocol for the transition. Most obesity medicine clinicians stop one drug and start the other at the lowest dose, re-titrating from the beginning. There is no pharmacological reason for a washout period: liraglutide has a half-life of about 13 hours, and tirzepatide about five days. Switching from Zepbound to Saxenda means waiting approximately two to three weeks for tirzepatide to clear before expecting Saxenda to show a distinct effect, though clinically you can start Saxenda sooner.

Women who switch from Zepbound back to Saxenda, typically for insurance reasons, should expect less weight-loss effect at any equivalent stage. Some weight regain is common in the transition period. Your prescriber may want to set realistic expectations before the switch.

Accessing These Drugs: Practical Steps for 2025

1. Confirm your insurance status. Call your plan and ask specifically whether tirzepatide (Zepbound) and liraglutide 3 mg (Saxenda) are on the formulary for obesity, not just for diabetes.
2. Get your BMI and comorbidities documented. Your prescriber needs to document BMI, and any qualifying conditions such as hypertension, PCOS, prediabetes, or sleep apnea, before submitting a prior auth.
3. Ask about manufacturer programs. Both Eli Lilly and Novo Nordisk have patient assistance programs for income-qualifying patients.
4. If using compounded tirzepatide, verify the pharmacy license at FDA's 503B database and request a certificate of analysis.
5. Plan your contraception conversation. If you are of reproductive age, talk about contraception at the same appointment where you get the prescription.

Clinical Voices on This Comparison

The American Gastroenterological Association 2022 guidelines on obesity pharmacotherapy state: "GLP-1 receptor agonists approved for chronic weight management have demonstrated clinically meaningful and durable weight loss when combined with lifestyle intervention." The AGA guidelines specifically list liraglutide 3 mg as a first-line option but were published before Zepbound's approval; tirzepatide has since been incorporated into updated obesity medicine guidance.

The Obesity Medicine Association's 2023 position acknowledges that tirzepatide represents a step-change in achievable weight loss for appropriate candidates, though access and affordability remain the primary barriers.

"The question I get most from my patients is not 'which drug works better?' but 'which one will my insurance actually pay for this month?'" says Dr. Elena Vasquez, WomanRx Editorial Board member and obesity medicine specialist. "Efficacy is only part of the equation. A drug that works brilliantly but sits on a shelf because of a failed prior auth is not a treatment plan."